구제역(FMD) 백신 시장 : 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

The Global Foot and Mouth Disease (FMD) vaccines market was valued at USD 2.5 billion in 2023, with projections indicating a growth trajectory, with an anticipated CAGR of 7.7% from 2024 to 2032. This growth is largely fueled by the increasing frequency of FMD outbreaks, proactive measures by government entities, and a booming livestock product commercialization.

Foot and mouth disease (FMD) is a viral infection, highly contagious, impacting animals like pigs, cattle, goats, and sheep. The virus, part of the Picornaviridae family, presents symptoms, such as fever and blisters in the mouth, on the feet, and occasionally on the teats. The widespread prevalence of FMD globally is a key driver for the market expansion. For example, data from the World Organization for Animal Health in 2023 highlighted that the FMD virus is present in about 77% of the global livestock population, notably in regions like Africa, the Middle East, Asia, and South America.

Recognizing the profound effects of FMD on livestock health, agricultural productivity, and economic stability, governments globally are ramping up their FMD vaccination initiatives. These efforts aim to enhance vaccine accessibility, ensure widespread immunization, and promote international collaboration for FMD control and eradication. For instance, in August 2022, Queensland's government allocated USD 20 million to strengthen its FMD defense strategies.

The overall industry is segmented into vaccine type, animal type, distribution channel, and region.

The market segments vaccines into conventional and emergency types. Within conventional vaccines, there is a further division into aluminium hydroxide and saponin-based and oil-based. In 2023, conventional vaccines dominated the market with an 83.9% share. Several pivotal factors drive the demand for conventional FMD vaccines. FMD, affecting cloven-hoofed animals, can lead to severe economic repercussions in the livestock sector, including reduced productivity, trade limitations, and extensive control measures.

Vaccines for FMD are categorized based on the animal type into cattle, sheep and goats, pigs, and others. The cattle segment led the market with a valuation of USD 1.4 billion in 2023. Being primary hosts for the virus, cattle show heightened susceptibility to FMD, often manifesting severe symptoms like fever, lameness, and characteristic vesicles on their feet, mouth, and teats.

North America FMD vaccines market was valued at USD 703.4 million in 2023, with projections indicating a 6.7% CAGR through 2032. The rising adoption of FMD vaccines underscores a commitment to protecting livestock and the broader agricultural sector from this viral threat. With FMD outbreaks posing severe risks to livestock and the agricultural economy, there is an intensified focus on preventive strategies.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising research and development activities for animal healthcare
    • 3.2.1.2 Frequent FMD outbreaks
    • 3.2.1.3 Government initiatives and regulations
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory scenario
• 3.3 Growth potential analysis
• 3.4 Reimbursement scenario
• 3.5 Regulatory landscape
• 3.6 Technological landscape
• 3.7 New emerging therapies
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Conventional vaccines
  • 5.2.1 Aluminium hydroxide and saponin-based vaccines
  • 5.2.2 Oil-based vaccines
• 5.3 Emergency vaccines

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Cattle
• 6.3 Sheep and Goat
• 6.4 Pig
• 6.5 Other animals

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Veterinary hospitals and clinics
• 7.3 Government institutions
• 7.4 Retail pharmacies
• 7.5 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Biogenesis Bago
• 9.2 Biovet Private Ltd
• 9.3 Brilliant Bio Pharma Private Limited
• 9.4 BVI
• 9.5 C.H. Boehringer Sohn AG and Co. KG
• 9.6 Ceva Sante Animale
• 9.7 Indian Immunologicals Ltd.
• 9.8 Inner Mongolia Biwei Antai Biotechnology Co., Ltd.
• 9.9 Kenya Veterinary Vaccines Production Institute
• 9.10 Merck and Co., Inc.
• 9.11 MEVAC